Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.44

Margin Of Safety %

40

Put/Call OI Ratio

0.51

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.21

Price

7.28

Target Price

12.31

Analyst Recom

2.75

Performance Q

-14.37

Relative Volume

0.37

Beta

0.41

Ticker: GRFS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19GRFS7.720.333.9626894
2024-12-20GRFS7.540.331.2426900
2024-12-23GRFS7.680.420.015040
2024-12-24GRFS7.820.302.676480
2024-12-26GRFS7.860.3120.896533
2024-12-27GRFS7.640.3412.426705
2024-12-30GRFS7.410.370.676861
2024-12-31GRFS7.440.380.047186
2025-01-02GRFS7.550.370.177441
2025-01-03GRFS7.720.372.067682
2025-01-06GRFS7.870.380.237722
2025-01-07GRFS7.850.381.267724
2025-01-08GRFS7.580.382.277761
2025-01-09GRFS7.60.382.277761
2025-01-10GRFS7.280.3924.757818
2025-01-13GRFS7.210.4124.837917
2025-01-14GRFS7.060.4513.438171
2025-01-15GRFS7.460.4722.738292
2025-01-16GRFS7.290.505.218487
2025-01-17GRFS7.270.51999.998565
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19GRFS7.72- - 0.83
2024-12-20GRFS7.55- - 0.83
2024-12-23GRFS7.68- - 0.83
2024-12-24GRFS7.82- - 0.83
2024-12-26GRFS7.85- - 0.83
2024-12-27GRFS7.64- - 0.83
2024-12-30GRFS7.40- - 0.83
2024-12-31GRFS7.44- - 0.83
2025-01-02GRFS7.55- - 0.83
2025-01-03GRFS7.73- - 0.83
2025-01-06GRFS7.87- - 0.83
2025-01-07GRFS7.85- - 0.83
2025-01-08GRFS7.60- - 0.83
2025-01-09GRFS7.60- - 0.83
2025-01-10GRFS7.28- - 0.83
2025-01-13GRFS7.22- - 0.83
2025-01-14GRFS7.05- - 0.83
2025-01-15GRFS7.47- - 0.83
2025-01-16GRFS7.27- - 0.83
2025-01-17GRFS7.28- - 0.83
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19GRFS0.0011.731.49
2024-12-20GRFS0.0011.731.49
2024-12-23GRFS0.0011.821.49
2024-12-24GRFS0.0011.821.49
2024-12-26GRFS0.0011.821.48
2024-12-27GRFS0.0011.821.48
2024-12-30GRFS0.005.181.48
2024-12-31GRFS0.005.181.48
2025-01-02GRFS0.005.181.48
2025-01-03GRFS0.005.181.48
2025-01-06GRFS0.005.781.48
2025-01-07GRFS0.005.781.48
2025-01-08GRFS0.005.781.48
2025-01-09GRFS0.005.781.48
2025-01-10GRFS0.005.781.48
2025-01-13GRFS0.005.811.44
2025-01-14GRFS0.005.811.44
2025-01-15GRFS0.005.811.44
2025-01-16GRFS0.005.811.44
2025-01-17GRFS0.005.811.44
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.23

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

5.81

Beta

0.41

Average Sales Estimate Current Quarter

1863

Average Sales Estimate Next Quarter

Fair Value

10.16

Quality Score

90

Growth Score

92

Sentiment Score

16

Actual DrawDown %

71.7

Max Drawdown 5-Year %

-77.8

Target Price

12.31

P/E

28.99

Forward P/E

7.59

PEG

0.5

P/S

0.26

P/B

0.82

P/Free Cash Flow

EPS

0.25

Average EPS Est. Cur. Y​

0.83

EPS Next Y. (Est.)

1.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

2.4

Relative Volume

0.37

Return on Equity vs Sector %

-16.1

Return on Equity vs Industry %

-23.6

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.22

EBIT Estimation

Grifols, S.A.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 23000
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
stock quote shares GRFS – Grifols, S.A. Stock Price stock today
news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025
marketwatch GRFS – Grifols, S.A. yahoo finance google finance
stock history GRFS – Grifols, S.A. invest stock market
stock prices GRFS premarket after hours
ticker GRFS fair value insiders trading